Welcome to PsychU!

New ICD-10-CM Dementia Codes For Agitation In Alzheimer’s Dementia

Effective October 1, 2022, updates to the International Classification of Disease, 10th Revision clinical modification (ICD-10 CM) added new coding specificity options for recording diagnoses of dementia. The expanded codes may be used to capture details of dementia type, severity and more fully identify types of neuropsychiatric symptoms of dementia. This presentation introduced the improved coding options, and described the coding structure format used in the updated dementia code sections. New code guidance for agitation in Alzheimer’s dementia was compared to the International Psychogeriatric Association definition of agitation cognitive disorders. Dr. Carolyn Clevenger discussed the use of the codes in practice and the potential implications of the dementia code revisions on providing care for persons living with dementia.

Featuring

Carolyn-Clevenger

Carolyn Clevenger, DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA

Professor of Transformative Clinical Practice, Emory University School of Nursing, Clinical Director and Gerontological Nurse Practitioner at Integrated Memory Care Clinic

More
Carolyn Clevenger DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA, is Professor of Transformative Clinical Practice at the Emory University School of Nursing in Atlanta, Georgia. She serves as Clinical Director and Gerontological Nurse Practitioner at Emory’s Integrated Memory Care Clinic, a patient-centered medical home providing integrated memory care and primary care for persons living with dementia. She is a Past President of the Gerontological Advanced Practice Nurses Association, and Fellow of the American Association of Nurse Practitioners (AANP) and the Gerontological Society of America.
Mike-Crooks

Mike Crooks, PharmD, BCGP

Senior Long-Term Care Medical Science Liaison

Carolyn Clevenger DNP, RN, GNP-BC, AGPCNP-BC, FAANP, FGSA is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Mike Crooks, PharmD CGP is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)

Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.

US.CORP.X.23.00038 / US.CORP.V.23.00025 / US.CORP.D.22.00004